Search research articles
Contact Us
Filters
Showing results (71-80 of 89) with videos related to
Page
of 9
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association
|
November 26, 2025
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study
Tomokazu Sazuka, Katsunori Tatsugami, Suguru Shirotake, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
March 17, 2026
A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study
Shuzo Hamamoto, Masahiro Nozawa, Suguru Shirotake, et al.
Urologic Oncology
|
March 7, 2020
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients
Koichiro Ogihara, Eiji Kikuchi, Keisuke Shigeta, et al.
Clinical Genitourinary Cancer
|
May 21, 2018
History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy
Emina Kayama, Eiji Kikuchi, Keishiro Fukumoto, et al.
Japanese Journal of Clinical Oncology
|
November 9, 2018
Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma
Keiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, et al.
European Urology Focus
|
July 21, 2017
External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study
Nobuyuki Tanaka, Ryuichi Mizuno, Keiichi Ito, et al.
Urologic Oncology
|
November 10, 2016
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model
Nobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, et al.
Urologic Oncology
|
April 5, 2016
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
Nobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, et al.
Clinical Genitourinary Cancer
|
April 23, 2016
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma
Suguru Shirotake, Yota Yasumizu, Keiichi Ito, et al.
European Urology Focus
|
July 21, 2017
Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis
Nobuyuki Tanaka, Eiji Kikuchi, Kent Kanao, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 89) with videos related to
Sort By:
Page
of 9
International Journal of Urology : Official Journal of the Japanese Urological Association
|
November 26, 2025
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study
Tomokazu Sazuka, Katsunori Tatsugami, Suguru Shirotake, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
March 17, 2026
A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study
Shuzo Hamamoto, Masahiro Nozawa, Suguru Shirotake, et al.
Urologic Oncology
|
March 7, 2020
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients
Koichiro Ogihara, Eiji Kikuchi, Keisuke Shigeta, et al.
Clinical Genitourinary Cancer
|
May 21, 2018
History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy
Emina Kayama, Eiji Kikuchi, Keishiro Fukumoto, et al.
Japanese Journal of Clinical Oncology
|
November 9, 2018
Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma
Keiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, et al.
European Urology Focus
|
July 21, 2017
External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study
Nobuyuki Tanaka, Ryuichi Mizuno, Keiichi Ito, et al.
Urologic Oncology
|
November 10, 2016
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model
Nobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, et al.
Urologic Oncology
|
April 5, 2016
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
Nobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, et al.
Clinical Genitourinary Cancer
|
April 23, 2016
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma
Suguru Shirotake, Yota Yasumizu, Keiichi Ito, et al.
European Urology Focus
|
July 21, 2017
Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis
Nobuyuki Tanaka, Eiji Kikuchi, Kent Kanao, et al.
Page
of 9